Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma

Final analysis results of the LYRA study demonstrated that daratumumab in combination with CyBorD induction therapy and as maintenance yielded durable and deep responses in patients with newly diagnosed or recurrent MM irrespective of ASCT status, with no new safety signals. Read More ›

Subgroup Analysis of the FORTE Study by Risk Categories of Carfilzomib-Based Induction/Consolidation with or without Autologous Transplant and Lenalidomide or Carfilzomib-Lenalidomide Maintenance

A simulation modeling that incorporated clinically representative sequences for patients with transplant-ineligible NDMM and included attrition rates supports using the D-Rd regimen in the first-line setting instead of reserving it for later lines of therapy. Read More ›

Phase 1b TRIMM-2 Trial Results for Subcutaneous Talquetamab plus Daratumumab in Patients with RRMM

A subgroup analysis of the FORTE study found that carfilzomib-lenalidomide-dexamethasone induction/consolidation (KRd) plus ASCT and carfilzomib-lenalidomide maintenance provided survival benefit to patients of all cytogenetic risk groups, including patients at high risk. Read More ›

Current Selective KRAS G12C Therapies in Non–Small-Cell Lung Cancer and Future Direction for Research

Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talquetamab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination. Read More ›

Assessing Factors Predictive of Pneumonitis Development with Use of Targeted Therapies in Non–Small-Cell Lung Cancer

The chemistry behind selective KRAS G12C therapies and potential future research avenues were discussed in a recently released journal article. Read More ›

Best Selection of Line Therapy in Non–Small-Cell Lung Cancer without Genetic Alterations

In a recent study, researchers identified several factors associated with the development of pneumonitis with therapies targeting non–small-cell lung cancer. Read More ›

Immune Checkpoint Inhibitor Use in Non–Small-Cell Lung Cancer Causes Primarily Mild Adverse Events

Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article. Read More ›